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ABSTRACT
Tumor-associated macrophages (TAM) are well known as a key player in the tumor microenvironment,
which support cancer progression. More recently, a lineage of monocytes characterized by the expression
of the TIE-2/Tek angiopoietin receptor identiﬁed a subset of circulating and tumor-associated monocytes
endowed with proangiogenic activity. TIE-2 expressing monocytes (TEM) were found both in humans and
mice. Here, we review the phenotypes and functions of TEM reported so far in human cancer and their
potential use as markers of cancer progression and metastasis. Finally, we discuss the therapeutic
approaches currently used or proposed to target TEM.
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Introduction
Tumor-associated monocytes or macrophages (TAM) are highly
heterogeneous and plastic cells displaying pro-tumoral activities,
largely shaped by tumor microenvironmental cues. TAM are well
known to promote tumor vascularization, 1-3 metastasis,4,5 and
immune suppression in pre-clinical models6,7 and to correlate
with poor patient outcome.8 Recent trials have efﬁciently targeted
TAM in different tumor settings, thus demonstrating the feasibil-
ity of this approach.9,10 A unique subset of monocytes, which
express the Tek tyrosine kinase receptor TIE-2 (TEM: TIE-2
expressing monocytes) comprises a functionally distinct myeloid
lineage of paracrine inducers of angiogenesis and tumor growth,
identiﬁed in 2005 by De Palma and collaborators.11 In experimen-
tal mouse models, TEM recruited to tumors displayed a pro-
foundly M2-skewed phenotype12,13 and accounted for most of the
angiogenic activity of bone marrow-derived cells since the genetic
ablation of TIE-2 on TEM completely prevented tumor angiogen-
esis.11 TIE-2 binds to Angiopoietins 1–4 (ANG 1–4) and is criti-
cally involved in vascular embryogenesis and adult angiogenesis.14
Although TIE-2 has been long regarded as an endothelial cell-spe-
ciﬁc receptor, TEM, endothelial progenitor cells and pericyte pre-
cursors of mesenchymal origin express also TIE-2.11 In vitro,
TEM migrated toward angiopoietin-2 released by activated endo-
thelial cells (EC) and angiogenic vessels, suggesting a homing
mechanism for TEM to tumors.15 In 2007, Venneri et al. detected
TEM in human tumors, including those of the kidney, colon, pan-
creas and lung as well as soft tissue carcinomas, while they were
excluded from surrounding healthy tissues.15 We made similar
observation in human breast cancer (BC) and reported that TEM
are also highly pro-angiogenic16 and pro-lymphangiogenic cells.17
Further, TEM display an immune suppressive activity evidenced
by their ability to secrete IL-10 and VEGF in large amounts and
to dampen in vitro tumor-speciﬁc T-cell proliferation mediated
by tumor dendritic cells (DC).18 In line with the previous stud-
ies,19,20 we observed in sections of BC that TEM density inversely
correlated with the expression of HLA-DR on DC, thus limiting
their ability to present antigens. In addition, TEM, but not DC,
massively form multiple tight conjugates with Tregs in BC, and
induce in vitro a conversion of CD4C T cells into
CD25CCD127lowFoxP3C suppressive CD4C T cells. This conver-
sion was largely due to the overexpression of CD86 on TEM.
Last, the observation in mice of tumor microenvironment of
metastases (TMEM) and in BC patients of some parallel struc-
tures, where the presence of monocytes together with other cells
seem to be involved in the metastatic process, might set the bases
for a contribution of TEM toward human tumor cell
dissemination.4,21,22
In 2007, Venneri et al. reported also that TEM accounted for
2–7% of blood mononuclear cells in healthy donors and were dis-
tinct from rare circulating endothelial cells and progenitors. Fur-
ther, like their murine counterparts, circulating TEM displayed a
marked tumor proangiogenic activity when co-injected with
human A87 gliomas in immuno-compromised mice.15 It appears
clear that TEM start to emerge as central player in the tumor
microenvironment and tumor progression and dissemination.
We review here the pro-tumoral functions of TEM in human
cancers and the corresponding clinical strategies targeting them.
Origins of TEM
In 2012, Wong et al. conducted a whole genome analysis of
monocytes circulating in healthy donors, which they
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categorized in three groups based on their expression of CD14
and CD16: non-classical (CD14C/CD16CC), intermediate
(CD14CC/CD16C) and classical (CD14CC/CD16¡) mono-
cytes.23 A recent genomic analysis conﬁrmed the expression of
Tie-2, Endoglin and VEGF-R2 in the CD14CC/CD16C popula-
tion, and showed that it has the highest capacity to induce
CD4C T-cell activation.18,24 Circulating TEM are enriched but
not restricted to the intermediate subset, which expresses
higher levels of surface molecules involved in antigen-present-
ing cell–T cell interactions: particularly MHC class II, CD40
and CD74, CD40 and CD54.23
Although monocytes are commonly described as TAM pre-
cursors, it is not yet clear which of the two main circulating
monocytes populations, “Ly6CC inﬂammatory” or “Ly6C¡ resi-
dent” monocytes, is the main source of TAM in mice.25,26
Movahedi and colleagues labeled Ly6Chi and Ly6Clo monocytes
with latex beads and injected them into tumor-bearing mice.
The authors found labeled-TAM only in mice transplanted
with labeled Ly6Chi monocytes and postulated that inﬂamma-
tory but not resident monocytes contain TAM precursors.26 In
contrast, in tumor-bearing mice, depletion of tissue resident
macrophages with CSFR-1-speciﬁc antibodies (CSFR-1, colony
stimulating factor receptor 1) was balanced by an increase in
inﬂammatory monocytes and associated with depletion of
TAM from the tumor mass but not around the invasion front.25
A comparative gene expression proﬁling of murine tumor TEM
with that of TAM, myeloid-derived suppressor cells, inﬂamma-
tory and resident monocytes, and tumor-derived EC revealed
that TEM and TAM proﬁles were highly related and clearly dis-
tinct from that of EC. Circulating TEM express a gene signature
more closely related to resident monocytes and TIE-2C embry-
onic/fetal macrophages. Relative to TAM, TEM signature show
enhanced pro-angiogenic/tissue remodeling activity and lower
pro-inﬂammatory activity. Hence, resident monocytes and
TEMs on one hand, and inﬂammatory monocytes and TAM
appear to be committed to distinct functions in the tumor
microenvironment. The authors postulate that TIE-2C embry-
onic/fetal macrophages, resident blood monocytes, and tumor
TEMs represent distinct developmental stages of a TEM lineage
committed to execute physiologic proangiogenic and tissue-
remodeling programs, which can be coopted by tumors.12
However, additional studies are needed to understand the rela-
tionships between human TEM and TAM.
Other authors also hypothesize a common origin with endothe-
lial precursor cells (EPC): hematopoietic and circulating EPC origi-
nate from the bone marrow (BM) and have the capacity to
differentiate into EC in vivo and to participate to the formation of
new blood and lymphatic vessels.27 The contribution of EPC to the
vasculature of mouse tumors was ﬁrst underlined by Lyden and
colleagues, who reported that the transplantation of wild type BM
stem cells into angiogenic defective mice restores tumor growth
and angiogenesis.28 Blood and lymphatic human EPC derive from
CD34C hematopoietic progenitors29,30 and share endothelial spe-
ciﬁc markers with mature ECs, such as TIE-1, TIE-2, VEGFR-2,
VEGFR-3 or vascular endothelial (VE)-cadherin.31 In several
human cancers, EPC have been detected at higher frequency in the
peripheral blood of patients relative to healthy individuals30,32,33
and associated with poor patient survival, cancer dissemination
and progression.34 Further, EPC are home to sites of
neovascularization and have been found inserted, in very low num-
bers, into the tumor endothelium in several human cancers.35-37
However, to date, evidence for the contribution of EPC to human
tumor neovascularization remains scarce: Capillary forming
CD133C structures were detected in NSCLC,33 while circulating
EPC in multiple myeloma displayed a capillary-like network for-
mation in matrigel.38 Recently, we reported that CD34CCD133C
EPC possess the ability to differentiate in vitro into myeloid lym-
phatic endothelial cells (LEC) expressing VEGF-A, -C and -D that
consistently display hemangiogenic and lymphangiogenic activi-
ties.39 Finally and most importantly, myeloid LEC differentiated in
vitro in the presence of patient plasma recapitulated both the phe-
notype and the dual angiogenic functions of TEM inﬁltrating breast
tumors.17 Hence, the lineage relationships of EPC with angiogenic
monocytes or TEM, as well as the extent of their contribution to
neovascularization of human cancers remain to be clariﬁed, but a
possible link between the two lineages might not be completely
excluded.
TEM involvement in different human solid tumors
Even though the ﬁrst evidence of a pro-tumoral effect of TEM
in mice11 and the ﬁrst report of TEM in peripheral blood of
cancer patient dates back to 2007,40,15 only in the recent years
the complexity of the interactions between TEM and the tumor
microenvironment has been examined by several groups into
different human cancer settings, among which BC is the most
studied. While TEM have been reported in many cancer types
and frequently associated to a worse prognosis, they remain
less well characterized in other cancer types. Here, we review
and summarize the state of the art in this ﬁeld (Table 1).
Breast cancer
Relative to healthy women, metastatic BC patients have ele-
vated frequencies of TEM in their peripheral blood that
remained unchanged by chemotherapy (paclitaxel) or anti-
angiogenic (bevacizumab) therapy.41 We reported that in the
breast tumor microenvironment, most (> 95%) of monocytes
(CD11bC, CD14C CD45C cells) express high levels of TIE-2,
but also of VEGFR-1, which correlated with TIE-2 expression,
and we conﬁrmed that they are endowed with high pro-angio-
genic and pro-tumoral activities.17 These TEM functions and
phenotypes were shaped by the tumor microenvironment as
they decreased dramatically from tumor to adjacent non-neo-
plastic tissue and to peripheral blood.17,16
It is well known that BC is a deeply immunosuppressed envi-
ronment, characterized by an impaired APC presentation capacity,
due to lack of CD80 and CD86 expression,19 and by an increased
inﬁltration of Tregs.20 We recently showed that TEM have immu-
nosuppressive functions, which are mediated by TIE-2 and
VEGFR.18 By combining Boolean modeling and experimental
approaches,42 we have predicted in silico combinations of
treatments transitioning the highly pro-angiogenic phenotype of
BC TEM to the weak pro-angiogenic phenotype of their peripheral
blood counterparts and vice versa. In silico predicted treatments
were validated experimentally using patient TEM.We have uncov-
ered that complex cross-talks between TIE-2, VEGFR1, TNF-a
and TGF-b pathways control TEM angiogenic activity.16
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Importantly, we show that both immune suppressive effects and
pro-angiogenic activity mediated by TEM are controlled by the
synergistic action of TIE-2 and VEGFR kinase activity and could
be abolished by combined use of speciﬁc kinase inhibitors of these
receptors.18,16 Forget et al. show that macrophage colony-stimulat-
ing factor (CSF1) enhanced TEMpro-angiogenic activity by induc-
ing TIE-2 expression and lowered the threshold of Ang-2 signaling
needed to induce TEM migration toward breast tumor cells in
vitro.43 Consistent with the observations of Forget et al., exposure
of TEM to PlGF/TIE-2 kinase inhibitor/TGF-b combined treat-
ment impaired TEM pro-angiogenic activity and ability to migrate
toward tumors cells.16 Hence, the tumor microenvironment
attracts TEM in tumor areas of intense neo-vascularization17 asso-
ciated with high levels of Ang-2 expression.44 Ang-2 synergizes
with PlGF and TNF-a to trigger TEM pro-angiogenic activity, thus
tilting the balance toward a strongly immunosuppressive environ-
ment. Finally, the unraveled synergies between TIE-2 and
VEGFR-1 pathways and their ligands Ang-2 and PlGF, which
underlie TEM pro-angiogenic and suppressive activities, have a
strong predictive value for BC patient relapse-free survival.16
Other solid tumor types
Renal cell carcinoma (RCC)
Like in BC, TEM inﬁltrating RCC represent a large fraction
(62.12 § 17.4%) of CD45CCD14C monocytes and TIE-2
expression is largely induced in the TME relative to adjacent
non-tumor tissue. In RCC, the frequency of tumor-inﬁltrated
TEM correlates with tumor grade, patient stage, lymph node
and distant metastases. Further, the overall tumor microvessel
density correlates with TEM frequency.45
Hepatocellular carcinoma (HCC)
Similarly to RCC, in HCC tissue, most of CD14C cells are TEM.
Further, the frequency of TEM was signiﬁcantly higher in HCC
patients relative to healthy individuals and associated to cancer
and not to hepatitis C virus infection.46,47 In addition, the fre-
quency of TEM in peripheral blood correlates with that in the
tumor and with microvessel density and changes with the ther-
apeutic response or recurrence, thus establishing TEM as a
diagnostic marker for HCC and suggesting a role for TEM in
HCC-induced angiogenesis.46,47 In contrast to TEM inﬁltrating
BC,17 HCC TEM were found enriched in perivascular areas of
HCC tissues. Last, and opposite to these observations, one
study described that inﬁltration of TEM in hilar cholangiocarci-
noma (a cancer arising from the proximal biliary tree) deﬁnes a
subgroup of patients with beneﬁcial tumor characteristics and
prolonged survival.48
Colorectal cancer (CRC)
Inmarked contrast toHCC, BC andRCC, TEM represent aminor-
ity of CD14C cells in sections of CRC tissues.49 TEM frequency in
the peripheral blood of CRC patients and healthy individuals did
not differ signiﬁcantly49,50 but the levels of TIE-2 expression at the
surface of CD14C cells were signiﬁcantly higher in patients relative
to healthy individuals.49 More recently, the low levels of circulating
TEM in CRC were conﬁrmed, even after the addition of anti-
VEGF to standard chemotherapy.51 Finally, in CRC, TEM frequen-
cies and levels of TIE-2 expression did not correlate with tumor
microvessel density, tumor stage, or pathological and clinical end
points in CRC patients.49
Glioblastoma
In 2014, the group of Gomez-Manzano was the ﬁrst to describe
the presence of TEM in surgical samples of human malignant
gliomas after bevacizumab treatment and in preclinical xeno-
graft models of glioma.52 TEM are localized at the tumor
periphery in sections of human brain tissues and observed at
the leading edge of the tumor following anti-VEGF therapy.
The authors demonstrated that tumor TEM are associated with
Table 1. Summary of TEM detection and importance in tumor development in different cancer types
Cancer type Tumor TEM/circulating TEM TEM role and association with tumor features Ref.
BC TEM: > 95% of TAM Tumor TEM immune suppressive and pro-angiogenic
activity are both controlled by TIE-2 and VEGFR
pathways. TEM limit DC’s Ag presentation and
promote CD4C T-cell conversion into Tregs
16,17,18,43
BC (metastatic) Circulating TEM Elevated levels of circulating TEM in metastatic BC 41
RCC TEM: around 62% of TAM Tumor TEM frequency correlates with tumor grade,
patient stage, metastases and microvessel density
45
HCC TEM: most of TAM Tumor TEM correlate with circulating TEM and are
envisioned as a diagnostic marker for HCC. TEM
frequency correlates with microvessel density
46,47
Hilar cholangiocarcinoma TEM inﬁltration correlates with prolonged survival 48
CRC TEM: minority of TAM Low frequency of circulating TEM. No correlation with
tumor, microvessel density, stage, pathological and
clinical end points
49,50
Glioblastoma TEM are mostly at the tumor
periphery
TEM are associated with an invasive glioma phenotype
and are a proposed biomarker of resistance to anti-
angiogenic treatment
52,53
GEP-NE Circulating TEM 54
AML Circulating TEM TEM are associated with increased proliferative activity
of blasts and pro-angiogenic features
56
CLL Circulating TEM High frequency of TEM correlates with ANG-2 secreted
by CLL cells
58
Primary myeloﬁbrosis CD14brightCD16lowTie-2C TEM frequency is higher than in healthy donors 59
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the development of an invasive glioma phenotype. Two years
later, Gabrusiewicz et al. proposed TEM as a biomarker of
tumor resistance to classical anti-angiogenic therapies in
glioblastoma52,53 but, however, did not examine the presence of
TEM in patient peripheral blood.
Circulating TEM in the peripheral blood of patients
with solid tumors
Another open question resides on the presence of circulating
TEM, which in some cases can be correlated with an advanced
or metastatic status of tumors.
Peripheral blood TEM have been detected and reported in
gastroenteropancreatic-neuroendocrine (GEP-NE) cancer
patients, although they have not yet been characterized. In GEP-
NE tumors, besides an increased level of soluble TIE-2 in the
serum of metastatic patients, circulating TEM show an enhanced
expression of TIE-2 and can migrate in response to Ang-2.54
Further, circulating leukocyte populations not strictly assigned
to monocytes were reported as expressing TIE-2. The ﬁrst one rep-
resents up to 30% of circulating cells in ovarian cancer patients and
consists of a population of vascular leukocytes cells (VLC) charac-
terized by the expression of CD14, CD45, CD11c, CD11b, VE-cad-
herin, CD31 and CD146 (hence their names, due to the expression
of myeloid and vascular markers).55 VLC display a pro-angiogenic
phenotype, secrete TGF-b, VEGF, IL-8, pro-angiogenic molecules
and contribute to tumor angiogenesis in mouse models. In human
ovarian cancer, most of VLCs are TEM, but only 50% of them
express VE-cadherin. Interestingly, both VLC and TEM express
CD52 (a glycosylphosphatidylinositol-anchored protein showing
abundant surface expression in lymphoid neoplasia), which repre-
sents a promising target for adoptive immunotherapy of this
neoplasm.55
TEM in hematological tumors
In a few hematological tumors, the presence of TEM is just merely
described, but their importance is increasing. Noteworthy, a
remarkable percentage of acute myeloid leukemia (AML) patients
have circulating TEM.56 TIE-2 expression in AML is associated
with increased proliferative activity of leukemic blasts, potentially
through an Ang-1 autocrine loop. Last, these cells also express
VEGFRs, show potential pro-angiogenic features, 56 and exhibit
high FMS-related tyrosine kinase 3, a possible therapeutic interven-
tion point of the corresponding tyrosine kinase inhibitors.57 Fur-
ther, in chronic lymphocytic leukemia (CLL) patients, TEM counts
were found high and correlated with plasma ANG-2 secreted by
CLL cells.58 Finally, in primary myeloﬁbrosis, a myeloproliferative
neoplasm, the frequency of CD14bright CD16low TIE-2C cells—but
not of CD14lowCD16bright TIE-2C cells—was signiﬁcantly higher
than in healthy individuals or patients with polycythemia vera or
thrombocytemia.59
TEM in metastasis
Multiple evidence have suggested that TAM are critically
involved into the dissemination of several human solid tumors
by promoting tumor lymphangiogenesis and lymphatic remod-
eling, which are associated with lymph node metastasis and
poor patient outcome.60-67 The role of TEM in metastasis is
largely unknown but multiple recent observations have
depicted a possible relationship between TEM and circulating
tumor cells or TEM and tumor cell intravasation through the
tumor endothelium.
Cancer associated macrophage-like cells (CAMCL) express-
ing variable levels of TIE-2, CD14 and CD45 were speciﬁcally
detected in the peripheral blood of breast, pancreatic and pros-
tate cancer patients, but not found in healthy individuals.68
Although the relationship between CAMLC and TEM remain
yet largely unexplored, CAMLC may encompass a population
of TEM. CAMLC in peripheral blood were found bound to cir-
culating tumor cells (CTC), suggesting that CAMLC may con-
tribute to tumor cells dissemination by binding to CTC while
in circulation or by interacting with tumor cells at the tumor
site and migrating together into circulation.68 Moreover, the
involvement of TEM in tumor cell dissemination might be
strengthened by the observation in mice of TMEM. TMEM are
sites of tumor cell intravasation, consisting of direct contact
between a macrophage, an endothelial cell and a tumor cell.
Moreover, TMEM density correlates with metastasis in differ-
ent mouse models.4,21,22 Preliminary data have indicated that
human macrophages in TMEM may express TIE-2.4 and fur-
ther work is required to establish whether mouse and human
TMEM have parallel functions and share similar mechanisms
of tumor cell intravasation. Along these lines, we show that a
fraction of TEM were found inserted into tumor lymphatics,
but not with lymphatics of adjacent non-neoplastic tissue,
where TEM show drastically reduced expression of TIE-2 and
LEC markers.17 Interestingly, we observed that all BC patients
with metastasis to the lymph node (LN) show TEM inserted
into their tumor lymphatics, whereas this was only the case for
57% of the patients without LN metastasis. 17 Thus, given the
lymphangiogenic activity of TEM and the correlation between
tumor lymphatics with sentinel and non-sentinel LN metastasis
in BC,69,70 it is reasonable to suggest that TEM insertion into
lymphatics may contribute to the spreading of tumor cells to
the proximal LN. The underlying mechanisms of TEM pro-
metastatic activity and insertion into tumor LV are currently
under investigation in our group.
Therapeutic opportunities
Strategies targeting TEM
Preclinical and clinical strategies to target TAM have been
recently reviewed71,72 and fall into four main groups: (i) killing-
induced depletion of TAM either by drugs, immunotoxin-con-
jugated antibodies or by immune cells, (ii) prevention of
recruitment of macrophages to tumor through the blockade of
chemokine gradients such as SDF1 (stromal cell-derived factor
1) or CCL2, (iii) reprogramming pro-tumoral M2-like macro-
phages toward an antitumor (M1-like) phenotype, and (iv)
reprogramming of the immunosuppressive TME to enhance
tumor-speciﬁc T-cell response, e.g., through the use of CD40
agonistic antibodies or checkpoint blockade inhibitors.71,72
Most of the clinical strategies currently in progress are focused
on CSFR-1 inhibition and are mainly phase I or II clinical trials.
The rationale for using CSFR-1 inhibitors is largely based on
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the depletion or/and reprogramming of macrophages depend-
ing on the TME.71,72
TEM pro-angiogenic activity and recruitment to tumor is criti-
cally controlled by TIE-2-ANG axis, which has been the target of
therapeutic strategies in clinical trials summarized below and dis-
played in red in Fig. 1. TIE-2-ANG axis is involved in both physio-
logic and tumor angiogenesis, but since the physiologic vasculature
is quiescent, disruption of TIE-2-ANG axis is remarkable for the
lack of side effects typically associated with inhibitors of angiogene-
sis (hemorrhage, arterial thromboembolic events or proteinuria).
However, antiangiogenic therapy induces intratumoral hypoxia,
which directly modiﬁes TAM and other stromal cells, which in
turn become active promoters of the metastatic dissemination of
tumor cells. A promising molecule is AMG 386, a peptibody that
prevents the binding of ANG to TIE-2: Its efﬁcacy has been dem-
onstrated in many tumors alone or in combination with chemo-
therapy, and in particular in ovarian cancer (Fig. 1, intervention
1).71,73 Similarly, CVX-060 is a fusion protein composed of two
ANG-2-binding peptides. Aside from the TIE-2-ANG axis, also
the VEGF-VEGFR one (Fig. 1, intervention 2) alone or in combi-
nation is a critical target for current therapeutic approaches: CVX-
241 is a bispeciﬁc Ab-binding VEGF an Ang-2, whose efﬁcacy was
evaluated in a phase-II clinical trial either alone or in combination
with Axitinib (a kinase inhibitor of VEGFR-1, VEGFR-2,
VEGFR-3, PDGFRa/b and c-Kit), which discontinued due to lack
of tolerability in patients with previously treated metastatic renal
cell carcinoma.74 More recently, Nesvacumab (REGN910), an
ANG-2 function blocking Ab (which does not bind to ANG-1),
was evaluated in patients with different solid tumors (HCC, BC,
adrenocortical carcinoma, CRC, RCC, NSCLC and pancreatic
cancer) and showed acceptable safety and evidence of objective
treatment effects in one adrenocortical carcinoma patient and a
few hepatocellular carcinoma patients (Fig. 1, intervention 1).74
Nesvacumab is now entering a phase-II clinical trial and a phase-Ib
study in combination with Aﬂibercept (a fusion protein composed
of VEGFR binding portion fused to a Fc fragment) in patients with
advanced solid malignancies. CEP-11981 potently and speciﬁcally
inhibits VEGFR-1 and VEGFR-2 and its efﬁciency was evaluated
in patients with advanced, relapsed or refractory solid tumors in a
phase-I study. Although no patient experienced complete or partial
response, 44% of the patients had stable disease at 6weeks, which
occurredmore frequently in the higher dose cohorts.75
Re-programming of pro-tumoral TAM toward monocytes
able to promote antitumor-speciﬁc responses has emerged
recently as a powerful therapeutic strategy,71 which may apply
also to TEM (Fig. 1, intervention 3). We show that TIE-2 and
VEGFR-1 kinase activity synergistically control TEM angio-
genic16 and immune suppressive25 activities: The combined
blockade of these receptors with speciﬁc kinase inhibitors reprog-
rammed tumor TEM into monocytes sharing feature of myeloid-
derived DC, which in turn can present tumor antigens and
enhance tumor-speciﬁc T-cell responses. This treatment also
dampened tumor TEM angiogenic16 and lymphangiogenic16
activities, by decreasing TEM paracrine secretion of VEGFs.16
Most importantly, this combined kinase inhibitor treatment
abolished TEM immune suppressive activity by impairing the
aptitude of TEM to massively convert T cells into Tregs and to
secrete the immunosuppressive cytokines VEGF-A and IL-10.16
Finally, this treatment prevented also tumor TEM to interfere
with DC maturation.16 All these effects are summarized in Fig. 2.
Besides the therapeutic strategies targeting TIE-2-ANG axis,
we propose below a rationale for additional approaches target-
ing TEM (displayed in blue in Fig. 1). In ovarian cancer, most
of TEM co-express the leukocyte marker CD52, which is the
target of Alemtuzumab, a monoclonal antibody approved by
the FDA for the treatment of chronic lymphoid leukemia
(CLL).55 Alemtuzumab depletes circulating T and B
cells through antibody-dependent cellular cytolysis and
Figure 1. Therapeutic approaches targeting human TEM. On the left in red, strategies reported in clinical trials, while proposed strategies are shown on the right in blue.
Strategies aim at preventing the interaction of (1) TIE-2/ANG2 and/or (2) VEGF/VEGFR. (3) In BC, combined blockade of TIE-2 and VEGFR kinase activity induce reprogram-
ming of TEM toward an antitumoral functional phenotype, whose effects are summarized in Figure 2. Other approaches are based on (4) CD52-mediated TEM killing, (5)
co-inhibition of CSFR-1 and VEGFR axes, (6) combined IL-10 and VEGF-A blockades. (7) VEGFR-1 function blocking antibodies impair the differentiation of CD34C precursor
cells into angiogenic TEM.
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complement-mediated lysis, and thus might be useful to deplete
TEM in ovarian tumors (Fig. 1, intervention 4). The inhibition
of CSFR-1 in clinical trials resulted in effective TAM depletion
and objective clinical responses in > 50% of the patients. 71
Recently, Forget et al. observed that CSF-1 increased TIE-2 sur-
face expression on human TEM,43 while in PyMT tumor bear-
ing mice TIE-2 upregulation leads to an increased secretion of
VEGF-A and to TEM expansion. 76 Hence, we postulate that
co-inhibition of CSFR-1 and VEGFR axes may synergistically
impair human TEM recruitment and pro-tumoral activities
(Fig. 1, intervention 5). Along these lines, Priceman et al. dem-
onstrated that the combined inhibition of CSF-1R and
VEGF-R2 signaling pathways in Lewis lung carcinoma model
prevented the recruitment of TAM and the tumor from evading
anti-angiogenic therapies.77 Finally, targeting TEM secretion of
IL-10 and VEGF by use of speciﬁc function antibodies (Fig. 1,
intervention 6) might be synergic when combined with the
interventions described above.
Strategies reprograming TEM precursors
Importantly, human and mouse circulating TEM are already
committed to an angiogenic function11,15, and thus re-pro-
gramming or altering mobilization or progenitor cells might
result in improved disease outcome. We report that plasma
from BC patients induced differentiation of CD34C cord
blood progenitors into hemangiogenic and lymphangiogenic
CD11bC myeloid cells, which express TIE-2, whereas plasma
from healthy women did not have this effect.15 Consistently,
we observed that circulating CD11bC cells from BC patients,
but not from healthy women, displayed a similar dual angio-
genic activity.15 Further, the commitment in vitro of human
CD34C hematopoietic progenitors into CD11bC proangio-
genic cells was shown to involve PlGF and to be impaired by
VEGFR-1 function blocking antibodies (Fig. 1, intervention
7). 78 In line with these results, silenced PlGF expression in
the murine mammary carcinoma-derived cell line 4T1
impaired in vivo the commitment of myeloid precursors into
CD11bC angiogenic cells and dampened tumor growth and
vascularization.78 Preliminary results obtained recently in
our group suggest that in human BC, the signals and path-
ways that control the differentiation of TEM precursors into
lymphangiogenic TEM and those that support tumor TEM
lymphangiogenic activity differ. Hence, these results raise the
critical question of whether combining therapeutic strategies
targeting both TEM precursor differentiation and tumor
TEM pro-tumoral activities would improve patient relapse-
free survival and limit resistance to TEM-targeted therapies.
To address these issues, pre-clinical models of TEM truly
reﬂecting the functions and phenotypes of patient TEM are
required. In human BC, we report that more than 95% of
tumor TEM co-expressed TIE-2 and VEGFR-1 in a co-regu-
lated manner17 and synergistically control TEM proangio-
genic,16 immune suppressive,18 and lymphangiogenic17
activities. By contrast, we observed that in 4T1, FARN168,
and MMTV-PyMT, currently held as the closest model to
human BC model, a much lower fraction of TEM co-express
TIE-2 and VEGFR-1 (28%, 45% and 5% of monocytes,
respectively) and this co-expression was not co-regulated.
This observation questions the validity of these pre-clinical
models to the identiﬁcation of treatments that can translate
into effective therapeutic strategies in BC patients.
Concluding remarks
TEM have now been detected in multiple solid and hematologi-
cal human tumors and represent the main population of TAM
in BC, RCC and HCC. In most of cancers, TEM have been
reported to display an inherent vascular growth-promoting
activity, which is largely shaped by the TME or to be associated
with tumor vascularization. The tumor signals and the corre-
sponding TEM pathways that control TIE-2 expression, TEM
frequency and TEM angiogenic activity remain still poorly
understood. Nevertheless, ANG-2, PlGF and SDF-1 have
emerged as tumor factors critically controlling TEM pro-angio-
genic activity, and in parallel TIE-2 and VEGFR signaling axes
arose as an attractive therapeutic target. Most importantly,
besides their pro-angiogenic activity, TEM inﬁltrating BC
endow a lymphangiogenic, immune suppressive and pro-meta-
static activity. TEM also represent a circulating reservoir of cells
committed to a pro-angiogenic function, which in some can-
cers, but not others, function as a diagnostic marker. Thus,
TEM represent attractive therapeutic and diagnostic targets,
but further studies are needed to elucidate their pro-tumoral
functions and interactions with the TME.
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and prevents TEM to interfere with DC maturation.
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